---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-128050"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2022-12-19T23:59:59+00:00"
generated_at: "2026-06-21T02:36:09.972007+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics changes Chairman; Robert Ingram resigns, Mark Velleca appointed

## Summary
- Robert A. Ingram resigned as Chairman and Board member effective Dec 13, 2022; no disagreement with company.
- Mark A. Velleca, M.D., Ph.D. appointed Chairman of the Board on Dec 15, 2022.
- Board size reduced from 10 to 9 members upon Ingram's resignation.
- Velleca has been a board member since Aug 2021, formerly CEO of G1 Therapeutics.

## SEC filing metadata
- accession: 0001104659-22-128050
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2022-12-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000110465922128050/0001104659-22-128050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000110465922128050/tm2232856d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-128050
- JSON: https://secwatch.observer/filing/0001104659-22-128050.json
- Plain text: https://secwatch.observer/filing/0001104659-22-128050.txt

## Key facts
- Executive change
  Robert A. Ingram resigned as Chairman of the Board at Black Diamond Therapeutics, Inc..
  - Action: resigned
  - Role: Chairman of the Board
  source text: On December 13, 2022, Robert A. Ingram notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), including his position of Chairman of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000110465922128050/0001104659-22-128050-index.htm
- Executive change
  Mark A. Velleca was appointed as Chairman of the Board at Black Diamond Therapeutics, Inc..
  - Action: appointed
  - Role: Chairman of the Board
  source text: On December 15, 2022, upon the recommendation of the NCG Committee, the Board appointed current Board member Mark A. Velleca, M.D., Ph.D. to serve as Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701541/000110465922128050/0001104659-22-128050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.